ASCO 2021 Kidney Cancer

Viewing 1-20 of 48 articles

ASCO 2021: Systemic Therapy Considerations After Immunotherapy Combination or Monotherapy in Advanced Renal Cell Carcinoma

ASCO 2021: Sequencing Therapies in Advanced Kidney Cancer in the Contemporary Era – Integration of Multimodality Treatment in Advanced Kidney Cancer: The Roles of Surgery and Radiation Therapy

ASCO 2021: Sequencing Therapies in Advanced Kidney Cancer in the Contemporary Era – Integration of Multimodality Treatment in Advanced Kidney Cancer: Novel Therapeutics on the Horizon in Advanced Kidney Cancer

ASCO 2021: Clinical Activity of Durvalumab and Savolitinib in Met-Driven, Metastatic Papillary Renal Cancer

ASCO 2021: Randomized Phase Ib Study To Evaluate Safety, Pharmacokinetics and Therapeutic Activity of Simlukafusp α in Combination With Atezolizumab ± Bevacizumab in Patients With Unresectable Advanced/ Metastatic Renal Cell Carcinoma (Rcc) (NCT03063762)

ASCO 2021: Making Strides in the Treatment of Non-Clear Cell Carcinoma: Are We Ready for Adaptive and Biomarker-Driven Strategies?

ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426

ASCO 2021: Real-World Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Receiving Front-Line Axitinib plus Pembrolizumab Versus Ipilimumab plus Nivolumab

ASCO 2021: Vorolanib, Everolimus, and the Combination in Patients with Pretreated Metastatic Renal Cell Carcinoma (CONCEPT Study): A Randomized, Phase 3, Double-Blind, Multicenter Trial

ASCO 2021: CANTATA: Primary Analysis of a Global, Randomized, Placebo-Controlled, Double-Blind Trial of Telaglenastat (CB-839) + Cabozantinib Versus Placebo + Cabozantinib in Advanced/Metastatic Renal Cell Carcinoma Patients on Immune Checkpoint Inhibitor

ASCO 2021: Expanding VEGF Blockade Combination Therapeutic Options in Advanced Renal Cell Carcinoma

ASCO 2021: Health-Related Quality-of-Life (HRQoL) Analysis from the Phase 3 CLEAR Trial of Lenvatinib plus Pembrolizumab or Everolimus Versus Sunitinib for Patients with Advanced Renal Cell Carcinoma (aRCC).

ASCO 2021: Phase II Trial of Durvalumab Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle-Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach: IMMUNOPRESERVE-SOGUG Trial

ASCO 2021: Pembrolizumab Versus Placebo As Post-Nephrectomy Adjuvant Therapy for Patients With Renal Cell Carcinoma: Randomized, Double-Blind, Phase III Keynote-564 Study

ASCO 2021: Analysis of the CLEAR Study in Patients with Advanced Renal Cell Carcinoma (RCC): Depth of Response and Efficacy for Selected Subgroups in the Lenvatinib (LEN) + Pembrolizumab (PEMBRO) and Sunitinib (SUN) Treatment Arms

ASCO 2021: Ipilimumab + Nivolumab in People with Rare Variant Renal Cell Carcinoma Refractory to Nivolumab Alone: Part 2 of UNISON (ANZUP 1602) Nivolumab Then Ipilimumab + Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

ASCO 2021: Efficacy of Avelumab + Axitinib (A + Ax) Versus Sunitinib (S) by IMDC Risk Group in Advanced Renal Cell Carcinoma (aRCC): Extended Follow-up Results from JAVELIN Renal 101

ASCO 2021: First Results of a Randomized Phase IB Study Comparing Nivolumab/ipilimumab with or Without CBM-588 in Patients with Metastatic Renal Cell Carcinoma

ASCO 2021: Post Hoc Analysis of the CLEAR Study in Advanced Renal Cell Carcinoma (RCC): Effect of Subsequent Therapy on Survival Outcomes in the Lenvatinib (LEN) + Everolimus (EVE) Versus Sunitinib (SUN) Treatment Arms

ASCO 2021: A Phase 2 Single-Arm Study of Cabozantinib in Patients with Advanced or Unresectable Renal Cell Carcinoma Pretreated with One Immune Checkpoint Inhibitor: The BREAKPOINT Trial (MeetUro Trial 03-NCT03463681)

1
2
3